Subject: OneQor Pharmaceutical (TRTC) Land Abbot Labs Vet as Chief Scientific Officer

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
OneQor Pharmaceutical (TRTC) Adds Dr. Joseph Fortunak, Innovator in the Pharmaceutical Industry with Extensive Background, as its Chief Scientific Officer
Hot Stock to WatchHot Stock to Watch

Company: Terra Tech Corp (OTCQX: TRTC)


Price: 0.28

Change (%): + 0.00 (0.00)

Volume: 96,037
TRTC Chart

OneQor Pharmaceutical Appoints Dr. Joseph Fortunak as Chief Scientific Officer

PHOENIX, AZ / ACCESSWIRE / November 6, 2019 / OneQor Pharmaceutical (“OneQor” or the “Company”), a fully integrated developer and supplier of proprietary, plant-derived products to the pharmaceutical, health, beauty, fitness, and wellness industries which has entered into an Agreement and Plan of Merger to merge with a subsidiary of Terra Tech Corp. (OTCQX:TRTC), today announced the appointment of Dr. Joseph Fortunak as its Chief Scientific Officer. Dr. Fortunak has served as Chair of the Science Committee for OneQor, since February 2019 and has spent 21 years in the pharmaceutical industry, with former roles including head of global chemical development at Abbot Labs.

Joseph Fortunak is a Professor of Chemistry and Pharmaceutical Sciences at Howard University in Washington D.C. Dr. Fortunak also holds honorary appointments at several other institutions in the US and overseas. He previously spent 21 years as an innovator in the pharmaceutical industry, where he contributed to the launch of 15 new drugs and 25+ new generic products whose total sales exceeded $100 billion. Dr. Fortunak’s research includes Green Chemistry; novel, leapfrogging technologies; and pharmacokinetic enhancers to reduce the cost/toxicity of medicines and promote sustainable, global access. He has received numerous awards including the American Chemical Society “Heroes of Chemistry”, and a US FDA Honor Award for Excellence and Innovation in Africa. Dr. Fortunak has over 100 publications and 35+ patents and patent applications.

Matthew Morgan, OneQor’s Chief Executive Officer, said, “Dr. Fortunak serves as the Chair of the Science Committee and, in this role, has demonstrated his invaluable insights into plant-based products and unwavering support for our mission to develop superior products backed by science. With his appointment as Chief Scientific Officer, he joins our world leading team of research scientists, cannabis-as-medicine experts and large-scale pharmaceutical manufacturers. In his role he will lead the development of new product formulations that benefit patients and consumers, as well as, creating immensely valuable Intellectual Property that benefits the Company.”

Continue Reading

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks